GlaxoSmithKline Consumer Healthcare

Transcription

1 Strong pricing power, Attractive valuations "BUY" February 09, 2016 Amnish Aggarwal Gaurav Jogani Rating BUY Price Rs5,837 Target Price Rs6,940 Implied Upside 18.9% Sensex 24,021 Nifty 7,298 (Prices as on February 09, 2016) Trading data Market Cap. (Rs bn) Shares o/s (m) M Avg. Daily value (Rs m) 97.5 Major shareholders Promoters 72.46% Foreign 10.23% Domestic Inst. 2.34% Public & Other 14.97% Stock Performance (%) 1M 6M 12M Absolute (10.6) (7.4) 3.2 Relative (7.0) How we differ from Consensus EPS (Rs) PL Cons. % Diff Price Performance (RIC: GLSM.BO, BB: SKB IN) (Rs) 8,000 7,000 6,000 5,000 4,000 3,000 2,000 1,000 0 Apr 15 Source: Bloomberg Aug 15 Feb 16 We are increasing FY16 and FY17 EPS estimates by % factoring in benefits of price increase and Novartis OTC business. GSK continues to gain share in MFD segment due to stronghold of Horlicks and Boost. However, 11% price increase in the past six months and likely entry of Patanjali remains a concern. Although SMP prices are down 18% YoY and remain benign, gradually increasing barley, sugar and wheat prices will cap further increase in gross margins, in our view. We expect GSK to sustain leadership led by strong brands, innovations and rising distribution reach; expect 12% PAT CAGR over FY16 18 due to peak margins in FY16. We remain positive given that GSK has 1) Valuations (28.2xDec17EPS) at a discount to coverage universe 2) strong leadership in MFD segment 3) 22% PAT CAGR in past 10 years and 4) likely upside from Novartis OTC business. Retain Buy Revenues up 1.7%, Adj.PAT up 36.8%: Revenues increased 1.7%, 7% adjusted for phase out of excise duty benefits, despite 1% impact of Chennai floods. Gross margins increased 400bps to 70.5%. EBITDA margins increased 500bps as 590bps higher employee cost was neutralised by 520bps lower ad spend and 180bps lower other expenses. EBITDA increased 50.9%. PBT grew by 37.5% on muted increase of 5.3% in depreciation and 3.8% in financial other income. Adj. PAT grew by 36.8 % at Rs1.38bn as tax rate increased by 30bps to 34.9%. Concall Takeaways: 1) MFD Volumes were flat, ( 1.5% in Q2). 2) Rural demand remains benign, small packs are impacted the most 3) Q3 auxiliary income increased by 9% due to pipeline correction in OTC products 4) Chennai floods impacted sales by 1% as 90% of Boost sales is from South India (Tamil Nadu is 45%) 4) GSK has increased MFD prices by 6% from Jan2016 post a 5% increase taken in July2015 5) GSK has added outlets in, taking the total reach to 3.3m 6) Novartis OTC products will be marketed by GSK from July and are expected to have retail sales of >Rs1bn in FY17 7) Malt, Wheat and Sugar prices are up 1 6%, SMP prices are down 18% YoY. Key financials (Y/e March) E 2017E 2018E Revenues (Rs m) 43,076 44,889 50,892 57,811 Growth (%) (11.5) EBITDA (Rs m) 7,301 9,016 10,203 11,549 PAT (Rs m) 5,836 7,161 8,045 9,041 EPS (Rs) Growth (%) (13.5) Net DPS (Rs) Profitability & Valuation E 2017E 2018E EBITDA margin (%) RoE (%) RoCE (%) EV / sales (x) EV / EBITDA (x) PE (x) P / BV (x) Net dividend yield (%) Source: Company Data; PL Research Result Update Prabhudas Lilladher Pvt. Ltd. and/or its associates (the 'Firm') does and/or seeks to do business with companies covered in its research reports. As a result investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of the report. Investors should consider this report as only a single factor in making their investment decision. Please refer to important disclosures and disclaimers at the end of the report

2 Exhibit 1: Sales up 1.7% despite Chennai floods and 530bps impact of excise benefit phase out, EBITDA margins expands 500bps YoY gr. (%) 9MFY16 9MFY15 YoY gr. (%) Net Revenue 10,295 10, ,257 32,002 30, Gross Profit 7,255 6, ,524 22,023 19, % of NS Advertising & Promotion (22.9) (5.9) % of NS Total Expenses 8,697 9,066 (4.1) 8,880 26,038 26,258 (0.8) % of NS EBITDA 1,598 1, ,377 5,964 4, Margins % Depreciation Interest Financial other Income ,691 1, PBT 2,026 1, ,812 7,220 5, Tax ,508 2, Adjusted PAT 1, ,843 4,712 3, sales grew 1.7%, 7% excluding excise impact, HFD gained 1.1% market share Exhibit 2: Poor demand environment, Floods and excise phase out impacts sales growth 14,000 12,000 10,000 8,000 6,000 4,000 2,000 Net Sales (Rs m) YoY gr. (%) (RHS) ,141 8,690 11,198 9,660 11,136 10,125 12,155 10,450 11,257 10, Q5FY14 Domestic MFD volumes were flat due to poor sachets and Boost sales Exhibit 3: Volumes remains sluggish as sachet prices and Chennai floods impact sales Q5FY February 09,

3 Benign SMP, price increases and malt prices help to boost gross margins Exhibit 4: Gross margins up 400bps due to benign input cost Gross Margin (%) EBITDA Margin (%) (RHS) Staff cost up by 590bps, Ad spends down 520bps and other expenditure down by 180bps Exhibit 5: Overheads: Ad spends down 23%; staff cost up 73% 60.0 Staff Costs (%) Advertising Spend (%) Other Exp (%) Exhibit 6: Sugar Prices: down 6.4% YoY and up 12.1% QoQ (Rs / MT) 3,600 3,400 3,200 3,000 2,800 2,600 2,400 2,200 3,355 3,380 3,215 2,750 2,838 2,843 May 13 Jun 13 Jul 13 Aug 13 Sep 13 Oct 13 Nov 13 Dec 13 Jan 14 Feb 14 Mar 14 Apr 14 May 14 Jun 14 Jul 14 Aug 14 Sep 14 Oct 14 Nov 14 Dec 14 Jan 15 Mar 15 Apr 15 May 15 Jul 15 Aug 15 Sep 15 Nov 15 Jan 16 3,215 Source: Bloomberg, PL Research February 09,

4 SMP prices are down 62% from its peak of Rs294.7/Kg Exhibit 7: Skimmed Milk Powder are down 21.6% YoY and up 2.2% QoQ (Rs / Kg) Dec 10 Feb 11 Apr 11 Jun 11 Aug 11 Oct 11 Dec 11 Feb 12 Apr 12 Jun 12 Aug 12 Oct 12 Dec 12 Feb 13 Apr 13 Jun 13 Aug 13 Oct 13 Dec 13 Feb 14 Apr 14 Jun 14 Aug 14 Oct 14 Dec 14 Apr 15 Aug 15 Source: Bloomberg, PL Research Exhibit 8: Barley Prices are up 16.9% QoQ and down 8.1% YoY (Rs / Quintal) 1,700 1,620 1,600 1,500 1,414 1,400 1,300 1,200 1,526 1,506 1,100 1,133 1,000 Aug 13 Sep 13 Nov 13 Dec 13 Feb 14 Mar 14 May 14 Jun 14 Aug 14 Sep 14 Nov 14 Dec 14 Mar 15 May 15 Jul 15 Sep 15 Jan 16 Source: Bloomberg, PL Research Exhibit 9: EPS increased by % factoring benefits of price increase and Novartis OTC business FY16E FY17E FY18E Earlier New % Change Earlier New % Change Earlier New % Change Net Sales (Rs m) 44,502 44, % 49,956 50, % 57,234 57, % Sales Growth (%) Gross margin (Rs m) 30,210 30, % 33,818 34, % 38,698 38, % Gross Margin (%) EBITDA (Rs m) 8,674 9, % 10,015 10, % 11,548 11, % EBITDA Margin (%) PAT (Rs m) 6,772 7, % 7,835 8, % 9,007 9, % PAT Growth (%) EPS (Rs) % % % Source: PL Research February 09,

5 Income Statement (Rs m) Net Revenue 43,076 44,889 50,892 57,811 Raw Material Expenses 11,771 10,813 12,719 14,543 Gross Profit 31,305 34,076 38,173 43,268 Employee Cost 4,313 5,028 5,547 6,359 Other Expenses 19,691 20,033 22,423 25,360 EBITDA 7,301 9,016 10,203 11,549 Depr. & Amortization Net Interest (2,211) (2,401) (2,604) (2,815) Other Income 2,219 2,409 2,611 2,822 Profit before Tax 8,891 10,807 12,141 13,644 Total Tax 3,055 3,646 4,096 4,604 Profit after Tax 5,836 7,161 8,045 9,041 Ex Od items / Min. Int. Adj. PAT 5,836 7,161 8,045 9,041 Avg. Shares O/S (m) EPS (Rs.) Cash Flow Abstract (Rs m) C/F from Operations 9,602 7,957 9,777 10,756 C/F from Investing (6,455) (4,088) (5,294) (5,846) C/F from Financing (2,939) (3,524) (4,284) (5,042) Inc. / Dec. in Cash (131) Opening Cash Closing Cash FCFF 7,677 6,437 8,937 9,936 FCFE 7,677 6,437 8,937 9,936 Key Financial Metrics Growth Revenue (%) (11.5) EBITDA (%) (16.3) PAT (%) (13.5) EPS (%) (13.5) Profitability EBITDA Margin (%) PAT Margin (%) RoCE (%) RoE (%) Balance Sheet Net Debt : Equity Net Wrkng Cap. (days) (64) (55) (53) (55) Valuation PER (x) P / B (x) EV / EBITDA (x) EV / Sales (x) Earnings Quality Eff. Tax Rate Other Inc / PBT Eff. Depr. Rate (%) FCFE / PAT Balance Sheet Abstract (Rs m) Shareholder's Funds 21,130 24,744 28,481 32,454 Total Debt Other Liabilities (944) (1,065) (1,201) (1,353) Total Liabilities 20,186 23,678 27,280 31,101 Net Fixed Assets 5,341 6,471 7,806 10,086 Goodwill Investments 22,606 24,953 28,247 31,092 Net Current Assets (7,760) (7,746) (8,773) (10,078) Cash & Equivalents Other Current Assets 10,846 11,727 13,209 14,612 Current Liabilities 18,966 20,177 22,885 25,464 Other Assets Total Assets 20,186 23,678 27,280 31,101 Quarterly Financials (Rs m) Y/e March Net Revenue 12,155 10,450 11,257 10,295 EBITDA 2,638 1,989 2,377 1,598 % of revenue Depr. & Amortization Net Interest Other Income Profit before Tax 2,982 2,383 2,812 2,026 Total Tax 1, Profit after Tax 1,968 1,550 2,194 1,319 Adj. PAT 1,968 1,550 1,843 1,319. February 09,

6 Prabhudas Lilladher Pvt. Ltd. 3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai , India Tel: (91 22) Fax: (91 22) Rating Distribution of Research Coverage PL s Recommendation Nomenclature % of Total Coverage 50% 40% 30% 20% 10% 0% 46.7% 42.1% 11.2% 0.0% BUY Accumulate Reduce Sell BUY : Over 15% Outperformance to Sensex over 12 months Accumulate : Outperformance to Sensex over 12 months Reduce : Underperformance to Sensex over 12 months Sell : Over 15% underperformance to Sensex over 12 months Trading Buy : Over 10% absolute upside in 1 month Trading Sell : Over 10% absolute decline in 1 month Not Rated (NR) : No specific call on the stock Under Review (UR) : Rating likely to change shortly DISCLAIMER/DISCLOSURES ANALYST CERTIFICATION We/I, Mr. Amnish Aggarwal (MBA, CFA), Mr. Gaurav Jogani (MBA), Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Terms & conditions and other disclosures: Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as PL ) is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security. The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein. Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor. Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication. PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document. PL is in the process of applying for certificate of registration as Research Analyst under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities. PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company. PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report. PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report. PL or its associates might have received compensation from the subject company in the past twelve months. PL or its associates might have managed or co managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months. PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months. PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report. PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report. It is confirmed that Mr. Amnish Aggarwal (MBA, CFA), Mr. Gaurav Jogani (MBA), Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report. The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all o the foregoing, among other things, may give rise to real or potential conflicts of interest. PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. DISCLAIMER/DISCLOSURES (FOR US CLIENTS) ANALYST CERTIFICATION The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report Terms & conditions and other disclosures: This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a 6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a 6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer. February 09,